SAB Biotherapeutics Inc (SABS)

Currency in USD
2.250
+0.020(+0.90%)
Real-time Data·
SABS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
SABS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.1202.345
52 wk Range
1.0006.600
Key Statistics
Prev. Close
2.23
Open
2.21
Day's Range
2.12-2.345
52 wk Range
1-6.6
Volume
107.97K
Average Volume (3m)
1.41M
1-Year Change
-14.23%
Book Value / Share
2.3
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SABS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.600
Upside
+415.56%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

SAB Biotherapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

SAB Biotherapeutics Inc Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

Compare SABS to Peers and Sector

Metrics to compare
SABS
Peers
Sector
Relationship
P/E Ratio
−0.6x−1.1x−0.5x
PEG Ratio
−0.02−0.060.00
Price/Book
1.0x2.3x2.6x
Price / LTM Sales
55.3x10.1x3.3x
Upside (Analyst Target)
303.6%293.2%45.1%
Fair Value Upside
Unlock26.5%7.4%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 11.600
(+415.56% Upside)

Earnings

Latest Release
May 09, 2025
EPS / Forecast
-0.56 / -0.12
Revenue / Forecast
-- / 230.00K
EPS Revisions
Last 90 days

SABS Income Statement

People Also Watch

0.740
PMN
-3.46%
7.222
TRON
-4.60%
0.872
GAME
+7.57%
0.96
KLTO
+4.35%
2.83
INMB
+10.73%

FAQ

What Stock Exchange Does SAB Biotherapeutics Trade On?

SAB Biotherapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for SAB Biotherapeutics?

The stock symbol for SAB Biotherapeutics is "SABS."

What Is the SAB Biotherapeutics Market Cap?

As of today, SAB Biotherapeutics market cap is 20.91M.

What Is SAB Biotherapeutics's Earnings Per Share (TTM)?

The SAB Biotherapeutics EPS (TTM) is -3.70.

From a Technical Analysis Perspective, Is SABS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has SAB Biotherapeutics Stock Split?

SAB Biotherapeutics has split 1 times.

How Many Employees Does SAB Biotherapeutics Have?

SAB Biotherapeutics has 63 employees.

What is the current trading status of SAB Biotherapeutics (SABS)?

As of 04 Aug 2025, SAB Biotherapeutics (SABS) is trading at a price of 2.25, with a previous close of 2.23. The stock has fluctuated within a day range of 2.12 to 2.35, while its 52-week range spans from 1.00 to 6.60.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.